



**Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: **Jeffrey Curtis, M.D., M.S., M.P.H.**

Committee: Joint meeting of the **Arthritis Advisory Committee** and the **Drug Safety & Risk Management Drug Advisory Committee**

Meeting Date: **January 11, 2019**

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item: Supplemental new drug application (sNDA) 021856 ULORIC (febuxostat), sponsored by Takeda Pharmaceuticals, which includes the results from the post-marketing safety trial required by FDA to evaluate the cardiovascular safety of febuxostat - the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities [CARES] trial. Febuxostat is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout. The discussion will include the results from the CARES trial, the benefit risk assessment of febuxostat, and potential regulatory actions, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Stocks/investments	(b) (6)	\$50,001 – \$100,000]
II. Other Imputed Interests		
None		

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/s/_____
Signature

_____/12/12/18_____
Date